DBCO-PEG4-Val-Cit-PAB MMAF
This product is a high-purity antibody–drug conjugate (ADC) payload featuring a DBCO group for copper-free strain-promoted alkyne–azide cycloaddition (SPAAC), a PEG4 spacer for solubility and reduced steric hindrance, a Val-Cit-PAB cleavable linker for cathepsin B-triggered release, and the potent tubulin polymerization inhibitor MMAF for targeted cancer therapy.
Key Features and Benefits
-
DBCO Group – Enables copper-free SPAAC click chemistry with azide-containing biomolecules for fast, bioorthogonal conjugation.
-
PEG4 Spacer – Improves aqueous solubility, flexibility, and reduces steric hindrance for better conjugation efficiency.
-
Val-Cit-PAB Linker – Cleavable by cathepsin B in lysosomes, ensuring tumor-selective payload release.
-
MMAF Payload – Highly potent antimitotic agent that disrupts microtubule formation, inducing apoptosis in target cells.
-
Targeted Delivery – Reduces systemic toxicity while enhancing therapeutic index in ADC applications.
-
High Purity – Supplied at >95% purity for consistent and reproducible performance.
Applications
-
Antibody–drug conjugates (ADCs) for targeted cancer therapy
-
Bioorthogonal click conjugation with azide-modified antibodies, proteins, or nanoparticles
-
Development of multifunctional imaging and therapeutic agents
-
Site-specific conjugation for research, preclinical, and diagnostic applications
Storage and Handling
-
Storage: Store at –20 °C, dry, and protected from light
-
Handling: Use anhydrous solvents such as DMSO or DMF; avoid moisture to preserve reactivity. Handle MMAF-containing compounds with appropriate protective measures
This product combines SPAAC click chemistry, a solubility-enhancing PEG4 spacer, a tumor-cleavable Val-Cit-PAB linker, and the potent MMAF payload specifically for precise, stable, and targeted drug delivery in ADC development.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
